Arbutus Biopharma Corporation (ABUS)

[DewDiligence]

ABUS discontinues COVID-therapeutics program:

https://www.globenewswire.com/news-release/2023/09/11/2741168/14025/en/Arbutus-Announces-Pipeline-Updates-and-Dosing-of-the-First-Subject-in-the-Phase-1a-1b-Clinical-Trial-with-AB-101-Cash-Runway-Extended.html

The company is… discontinuing its efforts to identify and develop a coronavirus combination therapy that included AB-343, its Mpro candidate, due to an unfavorable PK profile noted in the IND-enabling studies, and a potential nsp12 polymerase inhibitor.

ABUS also dropped development of AB-161, an HBV RNA destablizer, due to a safety problem.